$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024007948 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$205.0K	$156.0K	$488.0K
YoY Change	146.99%	21.88%	26.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.130M	$2.725M	$13.04M
YoY Change	1.52%	-11.47%	-1.05%
% of Gross Profit
Research & Development	$8.008M	$7.763M	$32.86M
YoY Change	-11.53%	20.51%	21.24%
% of Gross Profit
Depreciation & Amortization	$102.0K	$103.0K	$398.0K
YoY Change	13.33%	19.77%	68.64%
% of Gross Profit
Operating Expenses	$11.14M	$10.49M	$45.90M
YoY Change	-8.22%	10.17%	13.93%
Operating Profit	-$10.93M		-$45.41M
YoY Change	-9.28%		13.81%
Interest Expense	$926.0K	$1.008M	$4.069M
YoY Change	-1.49%	36.22%	157.37%
% of Operating Profit
Other Income/Expense, Net	$922.0K	-$13.00K	$3.971M
YoY Change	11.22%	-71.11%	231.47%
Pretax Income	-$10.01M	-$9.337M	-$41.44M
YoY Change	-10.8%	7.36%	7.07%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$10.01M	-$9.343M	-$41.44M
YoY Change	-10.8%	7.35%	7.07%
Net Earnings / Revenue	-4883.41%	-5989.1%	-8492.01%
Basic Earnings Per Share	-$0.22		-$0.93
Diluted Earnings Per Share	-$0.22	-$0.21	-$0.93
COMMON SHARES
Basic Shares Outstanding	44.68M shares	44.68M shares	44.68M shares
Diluted Shares Outstanding	44.68M shares		44.68M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.35M	$47.96M	$74.82M
YoY Change	-6.38%	-52.17%	-28.92%
Cash & Equivalents	$18.66M	$21.66M	$21.66M
Short-Term Investments	$42.70M	$26.31M	$53.17M
Other Short-Term Assets	$2.410M	$2.301M	$1.701M
YoY Change	-41.35%	-56.14%	-67.58%
Inventory
Prepaid Expenses	$2.410M	$2.301M
Receivables	$393.0K	$288.0K	$888.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$69.99M	$77.41M	$77.41M
YoY Change	-31.22%	-30.44%	-30.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.199M	$1.238M	$2.946M
YoY Change	-9.17%	-2.44%	-16.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.275M	$1.279M	$1.279M
YoY Change	-6.32%	-7.79%	-7.79%
Total Long-Term Assets	$4.048M	$4.225M	$4.225M
YoY Change	-15.6%	-13.9%	-13.9%
TOTAL ASSETS
Total Short-Term Assets	$69.99M	$77.41M	$77.41M
Total Long-Term Assets	$4.048M	$4.225M	$4.225M
Total Assets	$74.04M	$81.64M	$81.64M
YoY Change	-30.51%	-29.74%	-29.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.191M	$1.966M	$1.966M
YoY Change	78.14%	0.51%	0.51%
Accrued Expenses	$5.956M	$7.783M	$8.474M
YoY Change	30.76%	50.34%	47.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.84M	$10.44M	$10.44M
YoY Change	45.35%	33.71%	33.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.301M	$1.458M	$1.458M
YoY Change	-31.45%	-28.53%	-28.53%
Total Long-Term Liabilities	$1.301M	$1.458M	$1.458M
YoY Change	-31.45%	-28.53%	-28.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.84M	$10.44M	$10.44M
Total Long-Term Liabilities	$1.301M	$1.458M	$1.458M
Total Liabilities	$13.14M	$11.90M	$11.90M
YoY Change	30.84%	20.82%	20.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$348.8M	-$339.5M
YoY Change	12.75%	13.9%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.89M	$69.74M	$69.74M
YoY Change
Total Liabilities & Shareholders Equity	$74.04M	$81.64M	$81.64M
YoY Change	-30.51%	-29.74%	-29.74%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.01M	-$9.343M	-$41.44M
YoY Change	-10.8%	7.35%	7.07%
Depreciation, Depletion And Amortization	$102.0K	$103.0K	$398.0K
YoY Change	13.33%	19.77%	68.64%
Cash From Operating Activities	-$7.740M	-$7.139M	-$30.89M
YoY Change	-10.61%	-23.97%	-8.67%
INVESTING ACTIVITIES
Capital Expenditures	$80.00K	$8.000K	$582.0K
YoY Change	900.0%	-89.33%	-42.15%
Acquisitions
YoY Change
Other Investing Activities	$4.716M	$13.57M	$36.78M
YoY Change	-35.72%	91.25%	-6.07%
Cash From Investing Activities	$4.636M	$13.56M	$36.20M
YoY Change	-36.74%	93.18%	-5.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$107.0K	0.000	$0.00
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-$7.740M	-7.139M	-$30.89M
Cash From Investing Activities	$4.636M	13.56M	$36.20M
Cash From Financing Activities	$107.0K	0.000	$0.00
Net Change In Cash	-$2.997M	6.422M	$5.308M
YoY Change	125.34%	-370.97%	20.53%
FREE CASH FLOW
Cash From Operating Activities	-$7.740M	-$7.139M	-$30.89M
Capital Expenditures	$80.00K	$8.000K	$582.0K
Free Cash Flow	-$7.820M	-$7.147M	-$31.47M
YoY Change	-9.77%	-24.49%	-9.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-39902000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35558
CY2023	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	952-7570
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	64335342	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44677169	shares
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21655000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16347000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	53168000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	88920000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	288000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	771000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2301000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5246000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	77412000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	111284000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1238000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1269000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1708000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2251000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1279000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1387000	usd
CY2023Q4	us-gaap	Assets Assets	81637000	usd
CY2022Q4	us-gaap	Assets Assets	116191000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1966000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1956000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7783000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5177000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10440000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7808000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1458000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2040000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11898000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9848000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1068000	usd
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1044000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44677000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44677000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44677000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44677000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	409343000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	404834000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-67000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-395000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-339541000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298100000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	69739000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	106343000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81637000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116191000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	488000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	386000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	27107000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	45900000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-45412000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	4069000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1581000	usd
CY2023	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-98000	usd
CY2022	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-383000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3971000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1198000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-41441000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38704000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41465000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38728000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44677000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44677000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43600000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43600000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38704000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	328000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-253000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41113000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38957000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	usd
CY2023	crdf	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-41137000	usd
CY2022	crdf	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-38981000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4256000	usd
CY2022	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	75000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1000	usd
CY2022	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	139000	usd
CY2022	crdf	Preferred Stock Cumulative Dividend Adjustment PreferredStockCumulativeDividendAdjustment	414000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38704000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	106343000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4509000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	328000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-41441000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	69739000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-41441000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38704000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	398000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	236000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4509000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4256000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	921000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-632000	usd
CY2023	crdf	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	0	usd
CY2022	crdf	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	139000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-108000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1148000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-483000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	236000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3169000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	443000	usd
CY2023	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-543000	usd
CY2022	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-545000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2831000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1348000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-566000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-404000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-42000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30887000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33820000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	582000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1006000	usd
CY2023	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	114000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	86552000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	76445000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	70084000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	91233000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	20309000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	53829000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36195000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38149000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	75000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5308000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4404000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16347000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11943000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21655000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16347000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	232000	usd
CY2023	crdf	Non Cash Cumulative Preferred Stock Dividend Adjustment NonCashCumulativePreferredStockDividendAdjustment	0	usd
CY2022	crdf	Non Cash Cumulative Preferred Stock Dividend Adjustment NonCashCumulativePreferredStockDividendAdjustment	-414000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div>Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments.
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	74800000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.</span></div>
CY2023Q4	crdf	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	4300000	usd
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9459779	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9431303	shares
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	26293000	usd
CY2023Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	33000	usd
CY2023Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	17000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	26309000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	26942000	usd
CY2023Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	6000	usd
CY2023Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	89000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	26859000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53235000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	39000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	106000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53168000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	84299000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	19000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	394000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	83924000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	5016000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	1000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	21000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4996000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	89315000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	20000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	415000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	88920000	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	100000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	397000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	20750000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	175000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	600000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	500000	usd
CY2023	us-gaap	Depreciation Depreciation	400000	usd
CY2022	us-gaap	Depreciation Depreciation	200000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4990000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4682000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3752000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3413000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1238000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1269000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2737000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1849000	usd
CY2023Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	4309000	usd
CY2022Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	2333000	usd
CY2023Q4	crdf	Accruedresearchagreements Accruedresearchagreements	530000	usd
CY2022Q4	crdf	Accruedresearchagreements Accruedresearchagreements	509000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	207000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	486000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7783000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5177000	usd
CY2022	crdf	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	63000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	714000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	754000	usd
CY2023	us-gaap	Lease Cost LeaseCost	714000	usd
CY2022	us-gaap	Lease Cost LeaseCost	754000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1708000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2251000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1458000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2040000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2149000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2715000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	737000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	612000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	691000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	775000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	796000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	136000	usd
CY2023Q4	crdf	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2398000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	249000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2149000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2021Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
CY2021	crdf	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P3Y
CY2022	crdf	Class Of Warrant Or Right Number Expired ClassOfWarrantOrRightNumberExpired	129191	shares
CY2022	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	21.60
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4360968	shares
CY2022Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.33
CY2022	crdf	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P2Y1M6D
CY2023	crdf	Class Of Warrant Or Right Number Expired ClassOfWarrantOrRightNumberExpired	1553020	shares
CY2023	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	10.54
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2807948	shares
CY2023Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	2.45
CY2023	crdf	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P1Y10M24D
CY2023Q4	crdf	Preferred Stock Liquidation Preference Stated Value PreferredStockLiquidationPreferenceStatedValue	606000	usd
CY2022Q4	crdf	Preferred Stock Liquidation Preference Stated Value PreferredStockLiquidationPreferenceStatedValue	606000	usd
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1068000	usd
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1044000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5150000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	600000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4509000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4256000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4800000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4700000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-645000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-518000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8300000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	19054000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-789000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4902000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9089000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23956000	usd
CY2023Q4	crdf	Valuation Allowance ValuationAllowance	9089000	usd
CY2022Q4	crdf	Valuation Allowance ValuationAllowance	-23956000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8703000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8128000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	crdf	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	-2000	usd
CY2023	crdf	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	0
CY2022	crdf	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	32369000	usd
CY2022	crdf	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.84
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	902000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.02
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	553000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	515000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.01
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	319000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.01
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-126000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9089000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-23956000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.62
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23441000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20289000	usd
CY2023Q4	crdf	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	3611000	usd
CY2022Q4	crdf	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	2743000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1407000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1317000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9687000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4794000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1431000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39546000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30574000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	375000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	492000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	375000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	492000	usd
CY2023Q4	crdf	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	39171000	usd
CY2022Q4	crdf	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	30082000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39171000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30082000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	crdf	Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade	0	usd
CY2023	crdf	Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade	0	usd

Files In Submission

Name	View Source	Status
0001628280-24-007948-index-headers.html	Edgar Link	pending
0001628280-24-007948-index.html	Edgar Link	pending
0001628280-24-007948.txt	Edgar Link	pending
0001628280-24-007948-xbrl.zip	Edgar Link	pending
a231exq42023.htm	Edgar Link	pending
a311exq42023.htm	Edgar Link	pending
a312exq42023.htm	Edgar Link	pending
a321exq42023.htm	Edgar Link	pending
a322exq42023.htm	Edgar Link	pending
a97exq42023.htm	Edgar Link	pending
crdf-20231231.htm	Edgar Link	pending
crdf-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
crdf-20231231_cal.xml	Edgar Link	unprocessable
crdf-20231231_lab.xml	Edgar Link	unprocessable
crdf-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crdf-20231231_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crdf-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2024 Q1 Form 10-K Financial Statement

#000162828024007948 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2024 Q1 Form 10-K Financial Statement

#000162828024007948 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf